Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (894)	7/8/1997 2:03:00 PM
From: Biomaven	of 6136

Hi John. Thanks for the IMS numbers - please post any details you have. Here is an extract from a Dow Jones article released today on biotechs: _____ Only a small group of biotechs are profitable, and analysts say the company likeliest to break into that select group soon is Agouron Pharmaceuticals Corp. Agouron is the maker of Viracept, the fourth protease inhibitor approved by the FDA to treat AIDS patients. The drug is "taking the AIDS community by storm," according to Silverman. [Silverman is a Robertson, Stephens analyst] The First Call consensus estimate on Agouron is for a loss of 25 cents a share in the company's fiscal fourth quarter ended in June, compared with a loss of 17 cents a share in the year-ago quarter. But Crossen and Molowa believe the company will be profitable in the quarter ending in September. ____________ Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next